EOCN
Galmed Pharmaceuticals Ltd.
+0.28 (+8.21%)3.69USD9.8K成交股數–市值–本益比(近四季)–股價營收比–營收年增(近四季)–下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。外國發行人(20-F)通常只申報半年或年度,逐季會有缺。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q2 | 23Q1 | 22Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | – | – | – | – | – | – | – | – | – | – | – | – |
| 營業成本 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利率 | – | – | – | – | – | – | – | – | – | – | – | – |
| 研發費用 | 1.8M | – | 1.1M | 1.1M | – | – | 738K | 534K | – | 809K | – | 2.6M |
| 銷售管理費用 | 993K | – | 1.0M | 1.1M | – | – | 1.3M | 688K | – | 1.1M | – | 1.2M |
| 營業利益 | – | – | – | – | – | – | – | – | – | – | – | – |
| 營業利益率 | – | – | – | – | – | – | – | – | – | – | – | – |
| 稅後淨利 | −2.7M+147% | −1.9M-40% | −1.9M-1% | −2.5M+123% | −1.1M-13% | −3.2M+101% | −1.9M+5% | −1.1M-70% | −1.3M | −1.6M | −1.8M | −3.7M |
| 淨利率 | – | – | – | – | – | – | – | – | – | – | – | – |
| 稀釋 EPS | 2.86 | – | 0.33-86% | 5.06+207% | – | – | 2.31 | 1.65-27% | – | 0.95 | – | 2.25 |
| 稀釋股數 | 952K | – | 5.5M | 494K | – | 931K | 830K | 678K | – | 1.7M | – | 1.7M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q2 | 23Q1 | 22Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 2.9M | – | 3.3M | 5.0M | – | 4.7M | – | 1.8M | – | 1.0M | – | 2.0M |
| 應收帳款 | – | – | – | – | – | 672K | – | – | – | – | – | – |
| 存貨 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總資產 | 18.3M | – | 21.6M | 22.9M | – | 18.5M | – | 13.3M | – | 13.3M | – | 23.6M |
| 有息負債 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總負債 | – | – | – | – | – | – | – | – | – | – | – | – |
| 股東權益 | 12.7M | 13.9M | 19.1M | 20.5M | 16.9M | 16.3M | 18.4M | 11.8M | 12.8M | 10.6M | 12.0M | 20.7M |
| 負債比 | – | – | – | – | – | – | – | – | – | – | – | – |
| 淨現金(現金 − 有息負債) | – | – | – | – | – | – | – | – | – | – | – | – |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q2 | 23Q1 | 22Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | – | – | – | – | – | – | – | – | – | – | – |
| 資本支出 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流 | – | – | – | – | – | – | – | – | – | – | – | – |
| 折舊攤銷 | – | – | – | – | – | – | – | – | – | – | – | – |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | – | – | – | – | – | – | – | – | – | – | – |
營收拆解
這家公司的 XBRL 沒有標分部、產品或地區營收。多半是單一業務,或只在 10-K 文字裡揭露。
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | – | – | −10.3M | –% | 2.39 | – |
| FY2024 | – | – | −7.5M | –% | 8.08 | – |
| FY2023 | – | – | −6.9M | –% | 30.00 | – |
| FY2022 | – | – | −17.9M | –% | 127.80 | −18.5M |
| FY2021 | – | – | −32.5M | –% | 19.80 | −32.9M |
| FY2020 | 0 | – | −28.8M | –% | – | −26.3M |
| FY2019 | 0 | -100.0% | −20.5M | –% | – | −14.9M |
| FY2018 | 2.0M | – | −9.9M | -483.6% | – | −9.1M |